Meeting Coverage
ASH: Hematology
American Society of Hematology
Latest ASH: Hematology Meeting Coverage
Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk
Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease
Iptacopan improved hemoglobin without transfusion versus current standard of care
European trial is "practice-changing as of today," says U.S. expert
Most complete responses lasted 24 months or longer after limited-duration glofitamab
Phase III study showed 58% reduction in the risk of death versus chemo alone
Data from St. Jude cohort show higher rates of neurocognitive impairment
No difference in live birth rates with or without blood thinner
Glycoprotein receptor inhibitor produces four times as many responses as placebo
Also less likely for patients on Medicare and Medicaid
Similar outcomes if patients went directly to transplant or received intensive salvage first
Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients
Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone
"We should eliminate these silly neutropenic diets," expert says
Latest Oncology/Hematology Meeting Coverage
-
ASTRO: American Society for Radiation Oncology
October 2023
-
AVAHO: Association of VA Hematology/Oncology
September 2023
-
SOHO: Society of Hematologic Oncology
September 2023
-
AHNS: American Head & Neck Society
July 2023